34 related articles for article (PubMed ID: 38709242)
1. The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells.
Willson CM; Lequio M; Zhu Z; Wakefield MR; Bai Q; Fajardo E; Xiao H; Leung S; Fang Y
Anticancer Res; 2024 May; 44(5):1807-1815. PubMed ID: 38677738
[TBL] [Abstract][Full Text] [Related]
2. A Second Career for p53 as A Broad-Spectrum Antiviral?
Harford JB
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140618
[TBL] [Abstract][Full Text] [Related]
3. p53/MDM2 signaling pathway in aging, senescence and tumorigenesis.
Huang Y; Che X; Wang PW; Qu X
Semin Cancer Biol; 2024 May; 101():44-57. PubMed ID: 38762096
[TBL] [Abstract][Full Text] [Related]
4. Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure.
Zhang S; El-Deiry WS
Oncotarget; 2024 May; 15():275-284. PubMed ID: 38709242
[TBL] [Abstract][Full Text] [Related]
5. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
6. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.
Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T
Cancer Lett; 2010 Jan; 287(1):98-108. PubMed ID: 19577358
[TBL] [Abstract][Full Text] [Related]
7. Ras association domain family 1 isoform A suppresses colonic tumor cell growth through p21
Oh SJ; Lee MG; Moon JR; Lee CK; Chi SG; Kim HJ
J Gastroenterol Hepatol; 2019 May; 34(5):890-898. PubMed ID: 30226276
[TBL] [Abstract][Full Text] [Related]
8. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
Azmi AS; Philip PA; Aboukameel A; Wang Z; Banerjee S; Zafar SF; Goustin AS; Almhanna K; Yang D; Sarkar FH; Mohammad RM
Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
[TBL] [Abstract][Full Text] [Related]
10. Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53.
Lee JD; Menasche BL; Mavrikaki M; Uyemura MM; Hong SM; Kozlova N; Wei J; Alfajaro MM; Filler RB; Müller A; Saxena T; Posey RR; Cheung P; Muranen T; Heng YJ; Paulo JA; Wilen CB; Slack FJ
Cell Rep; 2023 Dec; 42(12):113478. PubMed ID: 37991919
[TBL] [Abstract][Full Text] [Related]
11. The SARS-CoV-2 spike protein induces lung cancer migration and invasion in a TLR2-dependent manner.
Kim MJ; Kim JY; Shin JH; Son J; Kang Y; Jeong SK; Kim DH; Kim KH; Chun E; Lee KY
Cancer Commun (Lond); 2024 Feb; 44(2):273-277. PubMed ID: 37702496
[No Abstract] [Full Text] [Related]
12. Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent?
Jahankhani K; Ahangari F; Adcock IM; Mortaz E
Biochimie; 2023 Oct; 213():130-138. PubMed ID: 37230238
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Spike Protein Post-Translational Modification Landscape and Its Impact on Protein Structure and Function via Computational Prediction.
Liang B; Zhu Y; Shi W; Ni C; Tan B; Tang S
Research (Wash D C); 2023 Mar; 6():0078. PubMed ID: 36930770
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
